CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

APX005M-002 is an open-label Phase 1-2 study and comprises a dose-escalation portion (Phase 1) followed by a Phase 2 tumor specific portion. Eligible subjects with non-small cell lung cancer or metastatic melanoma will receive intravenous APX005M in combination with nivolumab until disease progression, unacceptable toxicity or death, whichever occurs first. Study objectives include: * Determine the maximum tolerated dose and the recommended phase 2 dose of APX005M when given in combination with nivolumab * Evaluate safety of the APX005M and nivolumab combination * Evaluate the objective response rate, duration of response and median PFS by RECIST 1.1 in subjects with non-small cell lung cancer or metastatic melanoma receiving APX005M in combination with nivolumab * Determine the PK of APX005M